What is Acepodia?
Acepodia is a pioneering biotechnology enterprise focused on the development of first-in-class cell therapies. At the core of its innovation is the Antibody-Cell Conjugation (ACC) platform, a technology that enables the linkage of tumor-targeting antibodies to proprietary immune cells, including gamma delta T cells and natural killer (NK) cells. This approach creates novel antibody cell effector (ACE) therapies that demonstrate enhanced binding strength against tumors expressing low levels of antigens.
By prioritizing off-the-shelf, allogeneic solutions, Acepodia aims to overcome the logistical and scalability challenges associated with traditional autologous cell therapies. The company's leadership team, comprised of seasoned scientific experts, is dedicated to advancing a pipeline that emphasizes improved potency, safety, and broad applicability. This strategic focus on next-generation oncology positions Acepodia as a critical player in the evolution of cancer therapeutics, bridging the gap between laboratory innovation and clinical efficacy.
How much funding has Acepodia raised?
Acepodia has raised a total of $266M across 4 funding rounds:
Series A
$10M
Series B
$47M
Series C
$109M
Series D
$100M
Series A (2020): $10M, investors not publicly disclosed
Series B (2021): $47M led by Ridgeback Capital Management, The 8VC, CDIB Capital International, and DEFTA Partners
Series C (2021): $109M supported by Digital Mobile Venture
Series D (2023): $100M featuring Digital Mobile Venture
Key Investors in Acepodia
CDIB Capital International
A leading Asian private equity firm focused on middle-market growth capital and buyout transactions across healthcare, technology, and value-added manufacturing sectors.
DEFTA Partners
A global venture investment firm specializing in transformative healthcare technologies and information communication systems with a strong presence in North America and Asia.
The 8VC
A prominent venture capital firm that partners with entrepreneurs to build industry-changing technology companies, often focusing on deep-tech and healthcare innovation.
What's next for Acepodia?
With the recent infusion of $100M, Acepodia is well-positioned to accelerate its clinical trial programs and expand its manufacturing capabilities for its ACE therapy portfolio. The strategic roadmap involves scaling the development of its off-the-shelf platforms to ensure that these innovative treatments can reach a broader patient demographic efficiently. As the company moves deeper into clinical-stage development, the focus will likely shift toward regulatory milestones and potential partnerships that could further validate the ACC technology's market viability.
The ongoing support from institutional backers suggests a long-term commitment to Acepodia's vision of transforming cancer care. Future growth will be defined by the company's ability to demonstrate sustained clinical success and its capacity to navigate the complex regulatory environment governing advanced cell therapies. By maintaining its focus on high-potency, affordable oncology solutions, Acepodia remains a key entity to watch in the biotechnology sector.
